Tag: Ovarian Cancer
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership with GSK, to evaluate the potential of ... Read More
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) ... Read More
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More
ImmunoGen to get nearly $175m financing from Pharmakon Advisors
ImmunoGen, a US-based biotechnology company, will receive a non-dilutive term loan financing facility for up to $175 million from entities managed by Pharmakon Advisors. The ... Read More
TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial of its T-cell therapy candidate gavo-cel in ... Read More
Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy
Anixa Biosciences said that it has filed an investigational new drug (IND) application for its ovarian cancer CAR-T therapy with the US Food and Drug ... Read More
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of ... Read More
Refined white sugar may result in development of ovarian cancer in women
World Health Organisation says that refined white sugar can contribute to adverse health effects and it should be restricted in diet by 10 to 20 ... Read More
Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances
Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with ... Read More